Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Prevention of Irinotecan-Induced Diarrhea in Colorectal Cancer
NCT00040391Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in chemotherapy-induced diarrhea (CID), sponsored by Celgene Corporation. Started Jun 2002; status: terminated.
02
Drugs
thalidomide
03
Conditions
chemotherapy-induced diarrhea (CID)
Beyond the preview
Go deeper on NCT00040391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040391.